Taysha reports third quarter 2026 financial results
Net loss was $39.1 million, cash stood at $422.8 million, and TSHA-102 trials continue with topline data expected in 1H 2027.
See the latest news and media coverage for Taysha. We track all announcements, press releases, and industry mentions in real time, all in one place.
Gene therapy company for CNS monogenic diseases
tayshagtx.comLast updated
In short: Taysha completed pivotal REVEAL dosing, reported TSHA-102 gains and expected data and FDA feedback in 1H 2027.
Net loss was $39.1 million, cash stood at $422.8 million, and TSHA-102 trials continue with topline data expected in 1H 2027.
Completed dosing in pivotal and ASPIRE trials, reported $230M offering, and expects topline data and FDA feedback in 1H 2027.
The therapy achieved a 100% response rate in early trials. Taysha aims for BLA submission by late 2027.
The offering includes common stock and pre-funded warrants, with underwriters' option for additional 15%.
Taysha Gene Therapies posts Q3 GAAP EPS of -$0.10, beating estimates by $0.03, and expects $422.8 million in cash to support operations into H2 2028.
DALLAS, Aug. 11, 2026 -- Taysha Gene Therapies, Inc. a clinical-stage biotechnology company focused on advancing adeno-associated virus -based gene therapies for severe monogenic diseases...
Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6‑month interim analysis and FDA feedback on next steps toward BLA submission pathway...
The trial data showed that all 12 patients in the study experienced a gain or regain of developmental milestones by Month 12. This article was...
Track Taysha and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Taysha and other trending companies.